https://temple-quality-in-pharma.scribe-it.app/2026-lecture/1-sep14/3-regulations/Recent content in Regulations & Compendial Methods on Temple Quality in Pharma CourseHugoenMon, 07 Sep 2026 00:00:00 +0000https://temple-quality-in-pharma.scribe-it.app/2026-lecture/1-sep14/3-regulations/q1-stability/Sun, 06 Sep 2026 00:00:00 +0000https://temple-quality-in-pharma.scribe-it.app/2026-lecture/1-sep14/3-regulations/q1-stability/<picture><source type="image/avif" srcset="https://temple-quality-in-pharma.scribe-it.app/2026-lecture/1-sep14/3-regulations/q1-stability/image_hu_d85d902b65591715.avif 400w, https://temple-quality-in-pharma.scribe-it.app/2026-lecture/1-sep14/3-regulations/q1-stability/image_hu_898b562b2901abd1.avif 800w, https://temple-quality-in-pharma.scribe-it.app/2026-lecture/1-sep14/3-regulations/q1-stability/image_hu_1d412745d992903d.avif 1200w, https://temple-quality-in-pharma.scribe-it.app/2026-lecture/1-sep14/3-regulations/q1-stability/image_hu_4317d1cdb68f28a7.avif 1600w" sizes="100vw"><source type="image/webp" srcset="https://temple-quality-in-pharma.scribe-it.app/2026-lecture/1-sep14/3-regulations/q1-stability/image_hu_6ba64e6a71df705e.webp 400w, https://temple-quality-in-pharma.scribe-it.app/2026-lecture/1-sep14/3-regulations/q1-stability/image_hu_68a339066302b15b.webp 800w, https://temple-quality-in-pharma.scribe-it.app/2026-lecture/1-sep14/3-regulations/q1-stability/image_hu_48b92ad114383b64.webp 1200w, https://temple-quality-in-pharma.scribe-it.app/2026-lecture/1-sep14/3-regulations/q1-stability/image_hu_3254be2cc5abb8a8.webp 1600w" sizes="100vw"><img src="https://temple-quality-in-pharma.scribe-it.app/2026-lecture/1-sep14/3-regulations/q1-stability/image_hu_46e5afc97321d249.png" srcset="https://temple-quality-in-pharma.scribe-it.app/2026-lecture/1-sep14/3-regulations/q1-stability/image_hu_9122eb3d97664ca8.png 400w, https://temple-quality-in-pharma.scribe-it.app/2026-lecture/1-sep14/3-regulations/q1-stability/image_hu_46e5afc97321d249.png 800w, https://temple-quality-in-pharma.scribe-it.app/2026-lecture/1-sep14/3-regulations/q1-stability/image_hu_6d4a5360e944105b.png 1200w, https://temple-quality-in-pharma.scribe-it.app/2026-lecture/1-sep14/3-regulations/q1-stability/image_hu_8874ba987a997b63.png 1600w" sizes="100vw" alt="One-page overview of ICH Q1 stability testing. Panels cover: the one idea (a shelf life is a hypothesis that stability testing tests over time); the purpose (evidence on how quality varies with temperature, humidity and light, to set a re-test period or shelf life, storage statement and degradation pathways); the challenge of a moving target as the process evolves; the Q1A–Q1F family; stress testing versus R&amp;D forced degradation with key takeaways; an integrated forced &#43; accelerated &#43; long-term study design with the ~80 °C/2 weeks ≈ 2 years rule; significant change criteria and a three-year testing-frequency grid; climatic zones I–IVb; Q1B photostability, Q1D reduced designs, Q1E data evaluation; the modernized Q1 in development; the big picture from raw materials to patients; the analyst&#39;s role; and discussion questions." class="" loading="lazy" decoding="async" /> </picture> <h2 id="the-one-idea">The one idea</h2> <p>A shelf life is a <strong>hypothesis</strong>: <em>this product, in this package, stored this way, still meets its specification for N months.</em> Stability testing is the experiment that tests that hypothesis over real time. ICH Q1 is the agreed protocol for running that experiment so that the result means the same thing to every regulator.</p>https://temple-quality-in-pharma.scribe-it.app/2026-lecture/1-sep14/3-regulations/q2-validation/Sun, 06 Sep 2026 00:00:00 +0000https://temple-quality-in-pharma.scribe-it.app/2026-lecture/1-sep14/3-regulations/q2-validation/<picture><source type="image/avif" srcset="https://temple-quality-in-pharma.scribe-it.app/2026-lecture/1-sep14/3-regulations/q2-validation/image_hu_52b5d02018694ba8.avif 400w, https://temple-quality-in-pharma.scribe-it.app/2026-lecture/1-sep14/3-regulations/q2-validation/image_hu_5914cd9cf72865ed.avif 800w, https://temple-quality-in-pharma.scribe-it.app/2026-lecture/1-sep14/3-regulations/q2-validation/image_hu_f7e8e8617c7a2667.avif 1200w, https://temple-quality-in-pharma.scribe-it.app/2026-lecture/1-sep14/3-regulations/q2-validation/image_hu_7ef0ce50be359c6d.avif 1600w" sizes="100vw"><source type="image/webp" srcset="https://temple-quality-in-pharma.scribe-it.app/2026-lecture/1-sep14/3-regulations/q2-validation/image_hu_8678b793b257c811.webp 400w, https://temple-quality-in-pharma.scribe-it.app/2026-lecture/1-sep14/3-regulations/q2-validation/image_hu_20470bbe3a0590a1.webp 800w, https://temple-quality-in-pharma.scribe-it.app/2026-lecture/1-sep14/3-regulations/q2-validation/image_hu_9b089ae7e1980320.webp 1200w, https://temple-quality-in-pharma.scribe-it.app/2026-lecture/1-sep14/3-regulations/q2-validation/image_hu_837e5390736b4551.webp 1600w" sizes="100vw"><img src="https://temple-quality-in-pharma.scribe-it.app/2026-lecture/1-sep14/3-regulations/q2-validation/image_hu_f73c7fbfce57b879.png" srcset="https://temple-quality-in-pharma.scribe-it.app/2026-lecture/1-sep14/3-regulations/q2-validation/image_hu_c2ba2cb625a02cdf.png 400w, https://temple-quality-in-pharma.scribe-it.app/2026-lecture/1-sep14/3-regulations/q2-validation/image_hu_f73c7fbfce57b879.png 800w, https://temple-quality-in-pharma.scribe-it.app/2026-lecture/1-sep14/3-regulations/q2-validation/image_hu_559e773911af4084.png 1200w, https://temple-quality-in-pharma.scribe-it.app/2026-lecture/1-sep14/3-regulations/q2-validation/image_hu_80ed38716e3e41a9.png 1600w" sizes="100vw" alt="One-page overview of ICH Q2 — Validation of Analytical Procedures, subtitled &#39;Trust the measurement, support the decision.&#39; Panels cover: the one idea (an analytical result is a claim; validation is the evidence the measurement is fit for its intended purpose, and Q1 asks whether the product stays in specification over time while Q2 asks whether we can trust the evidence used to answer that); validation as a lifecycle rather than a check box, shown as a chevron flow — analytical target profile, develop, understand, optimize, validate, deploy, monitor, maintain/improve — with Q14 covering development and Q2 covering the demonstration of performance; the analytical procedure as a measurement system, with a table of components (sample preparation, reagents and reference materials, instrument, chromatographic conditions, data handling, analyst, software and environment, acceptance criteria) and how each influences the result; what we are trying to prove — fit for purpose, with identity, assay and impurity methods each having a different job and no universal validation package; the performance characteristics table (specificity/selectivity, range, response, accuracy, precision, detection limit, quantitation limit, robustness) each phrased as a question; specificity with non-specific versus specific chromatogram peaks and the tie to stability-indicating methods; accuracy and precision shown as archery targets; range, LOD and LOQ; robustness against deliberate reasonable variations in mobile phase, pH, column temperature, flow rate, sample prep and analysts/instruments; a stability-indicating method workflow — stress product, generate degradants, separate and analyze, confirm structures, validate method; validation strategy and deployment — same method at multiple sites, method transfer, platform methods, ongoing monitoring; the Q2 family with Q2(R2) and Q14 and the key R2 updates (lifecycle approach, reportable range, multivariate procedures, flexibility for justified alternatives); the big picture from Q1 stability through Q2 validation, Q3 impurities and Q6 specifications to Q8–Q14 quality by design, with science plus evidence equals control equals patient trust; and three discussion questions." class="" loading="lazy" decoding="async" /> </picture> <h2 id="the-one-idea">The one idea</h2> <p>An analytical result is a <strong>claim</strong>: <em>the assay is 98.7 %</em>, <em>this impurity is at 0.12 %</em>, <em>the API is identified</em>. Validation is the body of evidence that the measurement behind the claim is <strong>fit for its intended purpose</strong> — accurate enough, specific enough, precise enough, over the range where it is actually used — so that a release or stability decision can rest on it.</p>https://temple-quality-in-pharma.scribe-it.app/2026-lecture/1-sep14/3-regulations/q3-impurities/Sun, 06 Sep 2026 00:00:00 +0000https://temple-quality-in-pharma.scribe-it.app/2026-lecture/1-sep14/3-regulations/q3-impurities/<picture><source type="image/avif" srcset="https://temple-quality-in-pharma.scribe-it.app/2026-lecture/1-sep14/3-regulations/q3-impurities/image_hu_e69761227333d2c.avif 400w, https://temple-quality-in-pharma.scribe-it.app/2026-lecture/1-sep14/3-regulations/q3-impurities/image_hu_a58a8238ff01f9a9.avif 800w, https://temple-quality-in-pharma.scribe-it.app/2026-lecture/1-sep14/3-regulations/q3-impurities/image_hu_40c6910869c6228d.avif 1200w, https://temple-quality-in-pharma.scribe-it.app/2026-lecture/1-sep14/3-regulations/q3-impurities/image_hu_56a1e39bcec38aee.avif 1600w" sizes="100vw"><source type="image/webp" srcset="https://temple-quality-in-pharma.scribe-it.app/2026-lecture/1-sep14/3-regulations/q3-impurities/image_hu_76b0ee02df9b5cfc.webp 400w, https://temple-quality-in-pharma.scribe-it.app/2026-lecture/1-sep14/3-regulations/q3-impurities/image_hu_d349310bc22717ee.webp 800w, https://temple-quality-in-pharma.scribe-it.app/2026-lecture/1-sep14/3-regulations/q3-impurities/image_hu_1fbc50c91cd41ad8.webp 1200w, https://temple-quality-in-pharma.scribe-it.app/2026-lecture/1-sep14/3-regulations/q3-impurities/image_hu_4ebcfd73b46688cf.webp 1600w" sizes="100vw"><img src="https://temple-quality-in-pharma.scribe-it.app/2026-lecture/1-sep14/3-regulations/q3-impurities/image_hu_f86d0e9f7d3333f4.png" srcset="https://temple-quality-in-pharma.scribe-it.app/2026-lecture/1-sep14/3-regulations/q3-impurities/image_hu_ef9bc89693d25b32.png 400w, https://temple-quality-in-pharma.scribe-it.app/2026-lecture/1-sep14/3-regulations/q3-impurities/image_hu_f86d0e9f7d3333f4.png 800w, https://temple-quality-in-pharma.scribe-it.app/2026-lecture/1-sep14/3-regulations/q3-impurities/image_hu_223d0bc0bf8188c5.png 1200w, https://temple-quality-in-pharma.scribe-it.app/2026-lecture/1-sep14/3-regulations/q3-impurities/image_hu_dd3693e5aceec6c8.png 1600w" sizes="100vw" alt="One-page overview of ICH Q3 — Impurities, subtitled &#39;Know what&#39;s there. Control what matters.&#39; Panels cover: the one idea (a drug substance is never one molecule and a drug product is never just the active plus inert excipients — there are always other molecules from synthesis, shelf degradation, residual solvent, or catalyst metal, and Q3 turns toxicology into a number on a specification, asking is it there, how much, and is that amount safe; Q1 asks whether the product stays in specification over time, Q2 asks whether we can trust the analytical evidence, and Q3 asks how much of everything that is not the drug is acceptable and on what basis); the impurity control strategy as a chevron flow — classification (what it is), reporting (how much), identification (what it is), qualification (is it safe) — over four impurity classes: organic (process-related, drug-related, degradation products), inorganic (elements, salts, catalyst and reagent residues), residual solvents (four solvent classes, PDE, Option 1 or Option 2), and elemental impurities (24 elements, class 1/2A/2B/3, PDEs by route, risk assessment); the Q3 family table with Q3A(R2) organic impurities in a new drug substance (Step 4, Oct 2006), Q3B(R2) degradation products in a new drug product (Step 4, 2006), Q3C(R9) residual solvents (Step 4, Jan 2024) and Q3D(R2) elemental impurities (Step 4, Apr 2022); the reporting / identification / qualification threshold ladder drawn as a pyramid — no action below the reporting threshold, then reporting (threshold for awareness), identification (threshold for structure), qualification (threshold for safety) — with a note that the ladder scales with daily dose and the actual limits depend on the impurity, the drug, and the patient population; key concepts by guideline for Q3A, Q3B, Q3C and Q3D; the M7 overlay adding a genotoxic-impurity lens (TTC approach, (Q)SAR assessment, five structural classes, cohort of concern, nitrosamines and M7(R3)) that works together with Q3 rather than replacing it; an impurity-types-at-a-glance table and a process-related versus drug-related comparison (process-related from synthesis, removed by purification, a CMC/Q11 issue; drug-related formed from the drug itself, grows over shelf life, a Q1 stability issue); how it all fits together from Q1 stability through Q2 validation, Q3 impurities, Q6 specifications to Q8–Q14 quality by design, with science plus evidence equals control equals patient trust; and four discussion questions." class="" loading="lazy" decoding="async" /> </picture> <h2 id="the-one-idea">The one idea</h2> <p>A drug substance is never one molecule and a drug product is never just the active plus inert excipients. Alongside the thing you are selling there is always a population of <strong>other molecules</strong> — leftovers from the synthesis, things the molecule turned into on the shelf, solvent that never fully dried off, metal from a catalyst or a reactor wall. Every one of them is a question:</p>https://temple-quality-in-pharma.scribe-it.app/2026-lecture/1-sep14/3-regulations/q4-pharmacopoeial-harmonisation/Mon, 07 Sep 2026 00:00:00 +0000https://temple-quality-in-pharma.scribe-it.app/2026-lecture/1-sep14/3-regulations/q4-pharmacopoeial-harmonisation/<picture><source type="image/avif" srcset="https://temple-quality-in-pharma.scribe-it.app/2026-lecture/1-sep14/3-regulations/q4-pharmacopoeial-harmonisation/image_hu_cdc3fb2b7a62c0c8.avif 400w, https://temple-quality-in-pharma.scribe-it.app/2026-lecture/1-sep14/3-regulations/q4-pharmacopoeial-harmonisation/image_hu_f8dfbaa00c6fa472.avif 800w, https://temple-quality-in-pharma.scribe-it.app/2026-lecture/1-sep14/3-regulations/q4-pharmacopoeial-harmonisation/image_hu_d6acb17685898396.avif 1200w, https://temple-quality-in-pharma.scribe-it.app/2026-lecture/1-sep14/3-regulations/q4-pharmacopoeial-harmonisation/image_hu_c04cc1b487e23438.avif 1600w" sizes="100vw"><source type="image/webp" srcset="https://temple-quality-in-pharma.scribe-it.app/2026-lecture/1-sep14/3-regulations/q4-pharmacopoeial-harmonisation/image_hu_b64edcd378afef61.webp 400w, https://temple-quality-in-pharma.scribe-it.app/2026-lecture/1-sep14/3-regulations/q4-pharmacopoeial-harmonisation/image_hu_79ae304fd0dba08d.webp 800w, https://temple-quality-in-pharma.scribe-it.app/2026-lecture/1-sep14/3-regulations/q4-pharmacopoeial-harmonisation/image_hu_14c98f85e2f591d2.webp 1200w, https://temple-quality-in-pharma.scribe-it.app/2026-lecture/1-sep14/3-regulations/q4-pharmacopoeial-harmonisation/image_hu_18f841df3c5b7db2.webp 1600w" sizes="100vw"><img src="https://temple-quality-in-pharma.scribe-it.app/2026-lecture/1-sep14/3-regulations/q4-pharmacopoeial-harmonisation/image_hu_4158840427dadc9d.png" srcset="https://temple-quality-in-pharma.scribe-it.app/2026-lecture/1-sep14/3-regulations/q4-pharmacopoeial-harmonisation/image_hu_3e08f2058c7dc204.png 400w, https://temple-quality-in-pharma.scribe-it.app/2026-lecture/1-sep14/3-regulations/q4-pharmacopoeial-harmonisation/image_hu_4158840427dadc9d.png 800w, https://temple-quality-in-pharma.scribe-it.app/2026-lecture/1-sep14/3-regulations/q4-pharmacopoeial-harmonisation/image_hu_78685311119cd5ce.png 1200w, https://temple-quality-in-pharma.scribe-it.app/2026-lecture/1-sep14/3-regulations/q4-pharmacopoeial-harmonisation/image_hu_6eacc90b551eacc2.png 1600w" sizes="100vw" alt="One-page overview of ICH Q4, pharmacopoeial harmonisation. A banner reads &#39;One standard. Three regions. Global confidence.&#39; Panels cover: the one idea (Q1–Q3 are about methods you develop; Q4 is about the shared compendial baseline — sterility, dissolution, endotoxins, uniformity — and harmonisation removes duplicated testing without reducing quality); monograph versus general chapter, with the USP &lt;1000&gt; requirement/informational split; the three pharmacopoeias (USP–NF, Ph. Eur., JP) and the Pharmacopoeial Discussion Group, its identify–investigate–draft–consult–adopt–maintain cycle, the 2021 PDG reform and the Indian Pharmacopoeia Commission joining in 2022, and the split that PDG harmonises the text while ICH Q4B tells regulators it can be relied on; the Q4 family, showing Q4A stalled and Q4B (Step 4, 2007) as the evaluate-and-recommend mechanism; verification under USP &lt;1226&gt; versus a validated alternative method, and when the compendial method is mandatory; a big-picture strip linking Q1 stability, Q2 validation, Q3 impurities, Q6 specifications and Q8–Q14 quality by design; and discussion questions." class="" loading="lazy" decoding="async" /> </picture> <p><em>(The graphic is a lecture aid, not a citation — its &ldquo;Q4C / Q4D / Q4E&rdquo; rows and some panel labels don&rsquo;t match the current ICH text; the Q4 family is Q4B plus its fourteen annexes, as described below.)</em></p>https://temple-quality-in-pharma.scribe-it.app/2026-lecture/1-sep14/3-regulations/q5-biotech-products/Mon, 07 Sep 2026 00:00:00 +0000https://temple-quality-in-pharma.scribe-it.app/2026-lecture/1-sep14/3-regulations/q5-biotech-products/<picture><source type="image/avif" srcset="https://temple-quality-in-pharma.scribe-it.app/2026-lecture/1-sep14/3-regulations/q5-biotech-products/image_hu_6513429adda456d2.avif 400w, https://temple-quality-in-pharma.scribe-it.app/2026-lecture/1-sep14/3-regulations/q5-biotech-products/image_hu_3a9a4e5a886168f4.avif 800w, https://temple-quality-in-pharma.scribe-it.app/2026-lecture/1-sep14/3-regulations/q5-biotech-products/image_hu_9c400bd100209689.avif 1200w, https://temple-quality-in-pharma.scribe-it.app/2026-lecture/1-sep14/3-regulations/q5-biotech-products/image_hu_5379d76727cc47f6.avif 1600w" sizes="100vw"><source type="image/webp" srcset="https://temple-quality-in-pharma.scribe-it.app/2026-lecture/1-sep14/3-regulations/q5-biotech-products/image_hu_db20e73c18c1192e.webp 400w, https://temple-quality-in-pharma.scribe-it.app/2026-lecture/1-sep14/3-regulations/q5-biotech-products/image_hu_72ac20dfa498579c.webp 800w, https://temple-quality-in-pharma.scribe-it.app/2026-lecture/1-sep14/3-regulations/q5-biotech-products/image_hu_702c19d62669771e.webp 1200w, https://temple-quality-in-pharma.scribe-it.app/2026-lecture/1-sep14/3-regulations/q5-biotech-products/image_hu_e5ba4b12d8e283e4.webp 1600w" sizes="100vw"><img src="https://temple-quality-in-pharma.scribe-it.app/2026-lecture/1-sep14/3-regulations/q5-biotech-products/image_hu_e1bc8379f704e6c5.png" srcset="https://temple-quality-in-pharma.scribe-it.app/2026-lecture/1-sep14/3-regulations/q5-biotech-products/image_hu_8790d0e81a95fecb.png 400w, https://temple-quality-in-pharma.scribe-it.app/2026-lecture/1-sep14/3-regulations/q5-biotech-products/image_hu_e1bc8379f704e6c5.png 800w, https://temple-quality-in-pharma.scribe-it.app/2026-lecture/1-sep14/3-regulations/q5-biotech-products/image_hu_11827b87ba9f7d2f.png 1200w, https://temple-quality-in-pharma.scribe-it.app/2026-lecture/1-sep14/3-regulations/q5-biotech-products/image_hu_21ed8da8b174831f.png 1600w" sizes="100vw" alt="One-page overview of ICH Q5 — Quality of Biotechnological Products, subtitled &#39;the process is the product.&#39; Panels cover: the one idea (a biologic is a population of related molecules made in living cells, so the process is, to a large degree, the product) with the bigger-picture chain Q1 stability → Q2 validation → Q3 impurities → Q5 biotech; what makes a biologic different (microheterogeneity — glycoforms, charge and size variants, oxidation; process-dependent critical quality attributes — glycosylation, folding; adventitious-agent risk — viruses, mycoplasma, TSE agents); the Q5 family table (Q5A(R2) viral safety, Q5B expression construct, Q5C protein stability, Q5D cell substrates, Q5E comparability, with step dates) and the model that Q5B/Q5D control the source, Q5A controls the hazard, Q5C controls ageing and Q5E ties it together; the Q5A three-pillar viral-safety strategy — test cell lines and raw materials, demonstrate viral clearance by spiking model viruses and summing log reduction factors, test the product — with the R2 scope expansion and the retrovirus-like-particle clearance argument; the big picture from Q11 development through Q5D, Q5B, Q5A, Q3 impurities and Q5C stability to the Q6B specification, labelled build the product / control the quality / earn the patient&#39;s trust; the Q5D two-tier Master Cell Bank / Working Cell Bank system and the limit of in vitro cell age; Q5B verifying the coding sequence and genetic stability; Q5E comparability as a weight-of-evidence pyramid — analytical comparability as primary evidence, non-clinical and clinical bridging only if needed — with &#39;comparable, not identical&#39;; a protein-stability degradation-route table (aggregation, fragmentation/clipping, deamidation/isomerisation, oxidation, disulfide scrambling, loss of structure, potency loss) and how each is seen; the analytical toolkit (HPLC/UHPLC, CE-SDS, icIEF/IEX, LC-MS, ELISA/qPCR, bioassays) with the principles of orthogonality, multiple attributes and robust methods; and five discussion questions." class="" loading="lazy" decoding="async" /> </picture> <h2 id="the-one-idea">The one idea</h2> <p>A small-molecule drug substance is defined by a structure: draw the molecule, and any competent lab anywhere can make the same thing and prove it is the same thing. A <strong>biotechnological product</strong> — a monoclonal antibody, a therapeutic enzyme, a fusion protein, a vaccine antigen — is not like that. It is assembled by living cells, folded and decorated by cellular machinery, and purified out of a broth that also contains the cells&rsquo; own proteins, DNA, and — potentially — viruses. Change the cell line, the medium, the bioreactor, the purification train, or the formulation, and you can change the product itself in ways no structural drawing captures.</p>https://temple-quality-in-pharma.scribe-it.app/2026-lecture/1-sep14/3-regulations/q6-specifications/Mon, 07 Sep 2026 00:00:00 +0000https://temple-quality-in-pharma.scribe-it.app/2026-lecture/1-sep14/3-regulations/q6-specifications/<picture><source type="image/avif" srcset="https://temple-quality-in-pharma.scribe-it.app/2026-lecture/1-sep14/3-regulations/q6-specifications/image_hu_f237db585fe74920.avif 400w, https://temple-quality-in-pharma.scribe-it.app/2026-lecture/1-sep14/3-regulations/q6-specifications/image_hu_2b3ef570144f26ff.avif 800w, https://temple-quality-in-pharma.scribe-it.app/2026-lecture/1-sep14/3-regulations/q6-specifications/image_hu_41633586b9b70d29.avif 1200w, https://temple-quality-in-pharma.scribe-it.app/2026-lecture/1-sep14/3-regulations/q6-specifications/image_hu_c2cf64b6f462c274.avif 1600w" sizes="100vw"><source type="image/webp" srcset="https://temple-quality-in-pharma.scribe-it.app/2026-lecture/1-sep14/3-regulations/q6-specifications/image_hu_f55e0dfa24153952.webp 400w, https://temple-quality-in-pharma.scribe-it.app/2026-lecture/1-sep14/3-regulations/q6-specifications/image_hu_a5e116d0349a3750.webp 800w, https://temple-quality-in-pharma.scribe-it.app/2026-lecture/1-sep14/3-regulations/q6-specifications/image_hu_2cbdd58cda8ec27d.webp 1200w, https://temple-quality-in-pharma.scribe-it.app/2026-lecture/1-sep14/3-regulations/q6-specifications/image_hu_5d607e9b98bcf85c.webp 1600w" sizes="100vw"><img src="https://temple-quality-in-pharma.scribe-it.app/2026-lecture/1-sep14/3-regulations/q6-specifications/image_hu_5bd37b5217c9c49.png" srcset="https://temple-quality-in-pharma.scribe-it.app/2026-lecture/1-sep14/3-regulations/q6-specifications/image_hu_3653d2c57802e611.png 400w, https://temple-quality-in-pharma.scribe-it.app/2026-lecture/1-sep14/3-regulations/q6-specifications/image_hu_5bd37b5217c9c49.png 800w, https://temple-quality-in-pharma.scribe-it.app/2026-lecture/1-sep14/3-regulations/q6-specifications/image_hu_1ec5ef785a79dec3.png 1200w, https://temple-quality-in-pharma.scribe-it.app/2026-lecture/1-sep14/3-regulations/q6-specifications/image_hu_e62ea59649885988.png 1600w" sizes="100vw" alt="One-page overview of ICH Q6 — Specifications, subtitled &#39;The release contract. Quality, not just testing.&#39; Panels cover: the one idea (a drug substance is never one molecule and a drug product is never just the active plus excipients, so Q6 is where the earlier work — Q1 stability, Q2 validation, Q3 impurities, Q5 biotech — comes together as a finite list of tests, methods and acceptance criteria that confirm quality but do not create it, a safety and efficacy argument rewritten as a pass/fail line); what a specification is — the test (what attribute is judged), the analytical procedure (how it is measured, often a compendial chapter or a validated method), and the acceptance criterion (the limit, e.g. 98.0–102.0 %, ≤ 0.2 %, &#39;meets USP &lt;711&gt;&#39;) — one part of a broader control strategy alongside GMP, process control and stability; the Q6 family table with Q6A for chemical substances (Step 4, October 1999, with added decision trees) and Q6B for biotechnological/biological products (Step 4, March 1999), Q6A a checklist framework and Q6B a characterisation-first framework; the three pharmacopoeias (USP–NF, Ph. Eur., JP) and the Pharmacopoeial Discussion Group that harmonises shared texts, with Q4B telling regulators the harmonised text can be relied on; Q6A universal tests (description, identification, assay, related substances, residual solvents, elemental impurities, water content / residue on ignition) plus dosage-form-specific tests (oral solids, parenterals, inhalation/nasal, transdermal/topical) and the Q6A decision trees (polymorphism, impurities, microbial limits, dissolution, residual solvents, chirality); setting acceptance criteria as the overlap of two anchors — process capability (what the process actually delivers) and clinical relevance (what the patient has been exposed to) — with the limit set no wider than needed and the specification treated as a contract with the patient, not a wish list; Q6B characterisation (physicochemical properties, structure confirmation, impurities process- vs product-related, potency by bioassay, quantity) versus routine testing (identity, purity/impurities, potency), the product-related substance (no adverse effect) versus product-related impurity distinction, and the in-house primary-to-working reference standard chain; comparability as a weight-of-evidence pyramid — analytical data as primary evidence, non-clinical and clinical bridging only if needed — covering primary and higher-order structure, glycosylation, charge and size variants, purity, potency and stability; release versus shelf-life acceptance criteria (a tighter release limit and a wider shelf-life limit for the same attribute, formal dual limits in the EU and Japan, a single shelf-life limit in the US); and the Q6 connection strip running Q1 stability, Q3 impurities, Q5 biotech, Q6 specification, Q2 validation, Q7 GMP/QC — from characterisation to specification to validated methods to batch release — with six discussion questions." class="" loading="lazy" decoding="async" /> </picture> <p><em>(The graphic is a lecture aid, not a citation — its &ldquo;Q6C / Q6D / Q6E (Not used)&rdquo; rows and its &ldquo;Comparability — Q6E&rdquo; panel don&rsquo;t match the current ICH text: there is no Q6C/D/E, and product comparability lives in <a href="https://temple-quality-in-pharma.scribe-it.app/2026-lecture/1-sep14/3-regulations/q5-biotech-products/">Q5E</a>. The Q6 family is Q6A plus Q6B, as described below.)</em></p>https://temple-quality-in-pharma.scribe-it.app/2026-lecture/1-sep14/3-regulations/q7-gmp-api/Mon, 07 Sep 2026 00:00:00 +0000https://temple-quality-in-pharma.scribe-it.app/2026-lecture/1-sep14/3-regulations/q7-gmp-api/<picture><source type="image/avif" srcset="https://temple-quality-in-pharma.scribe-it.app/2026-lecture/1-sep14/3-regulations/q7-gmp-api/image_hu_a51685978159586f.avif 400w, https://temple-quality-in-pharma.scribe-it.app/2026-lecture/1-sep14/3-regulations/q7-gmp-api/image_hu_edaa493b598f46a8.avif 800w, https://temple-quality-in-pharma.scribe-it.app/2026-lecture/1-sep14/3-regulations/q7-gmp-api/image_hu_b50dff2bfdae5484.avif 1200w, https://temple-quality-in-pharma.scribe-it.app/2026-lecture/1-sep14/3-regulations/q7-gmp-api/image_hu_5f4775835d7d47cd.avif 1600w" sizes="100vw"><source type="image/webp" srcset="https://temple-quality-in-pharma.scribe-it.app/2026-lecture/1-sep14/3-regulations/q7-gmp-api/image_hu_7327ea862b618257.webp 400w, https://temple-quality-in-pharma.scribe-it.app/2026-lecture/1-sep14/3-regulations/q7-gmp-api/image_hu_a3951e2c1c5b71c1.webp 800w, https://temple-quality-in-pharma.scribe-it.app/2026-lecture/1-sep14/3-regulations/q7-gmp-api/image_hu_6b8372aec4f6368b.webp 1200w, https://temple-quality-in-pharma.scribe-it.app/2026-lecture/1-sep14/3-regulations/q7-gmp-api/image_hu_a12109f5593385bc.webp 1600w" sizes="100vw"><img src="https://temple-quality-in-pharma.scribe-it.app/2026-lecture/1-sep14/3-regulations/q7-gmp-api/image_hu_d12506877aa9b5d1.png" srcset="https://temple-quality-in-pharma.scribe-it.app/2026-lecture/1-sep14/3-regulations/q7-gmp-api/image_hu_7e20aa729d041ca2.png 400w, https://temple-quality-in-pharma.scribe-it.app/2026-lecture/1-sep14/3-regulations/q7-gmp-api/image_hu_d12506877aa9b5d1.png 800w, https://temple-quality-in-pharma.scribe-it.app/2026-lecture/1-sep14/3-regulations/q7-gmp-api/image_hu_65320dbcf183c7ba.png 1200w, https://temple-quality-in-pharma.scribe-it.app/2026-lecture/1-sep14/3-regulations/q7-gmp-api/image_hu_c38d73c1b4a9b74f.png 1600w" sizes="100vw" alt="One-page overview of ICH Q7 — GMP for Active Pharmaceutical Ingredients, subtitled &#39;Quality by Design. Quality by Control. Quality for Patients.&#39; Panels cover: the one idea (the earlier ICH sections are about the result; Q7 is about the system that produced it — a correct number from an uncalibrated instrument or a batch record written from memory is not evidence, and GMP is the floor the quality system stands on); where GMP begins (Table 1 — chemical synthesis, animal-source and plant-source APIs start at introduction of the API starting material, herbal extracts at further extraction, comminuted herbs at cutting, biotech at maintenance of the working cell bank, classical fermentation at introduction of the cells — with stringency increasing from early steps to final steps); the independent quality unit and its non-delegable duties (release or reject every batch, review and approve the batch record, ensure critical deviations are investigated, approve procedures and changes, ensure QC testing is done, release no batch until all requirements are met, oversee contract manufacturers) plus its authority to stop production and prevent marketing of a non-compliant batch; Q7 in the big picture (Q8–Q11 define the process and control strategy, Q7 builds the quality system, Q2 validates the methods, Q3 controls impurities, Q6 sets the release contract, Q1 confirms stability — Science &#43; GMP &#43; Control = Patient Trust); the numbered sections of Q7 (quality system, personnel, buildings and facilities, process equipment, documentation, materials management, production, in-process controls, packaging and labelling, storage and distribution, laboratory controls, validation, change control, deviation management, complaints and recalls, contract manufacturers, distribution chain, cell culture / fermentation); Section 11 laboratory controls (test raw materials, in-process samples and finished API; characterise the impurity profile and monitor trends; validate methods for their intended use; issue a certificate of analysis; stability monitoring and reserve samples; investigate and resolve out-of-specification results; maintain data integrity); Section 12 validation (process validation — prospective, concurrent or retrospective, lifecycle-based — and cleaning validation with justified health-based limits, validated swab/rinse methods, and worst-case shared equipment); reprocessing versus reworking; data integrity — ALCOA&#43; (attributable, legible, contemporaneous, original, accurate, complete, consistent, enduring, available); key takeaways (GMP is the floor, it starts at a defined point, many controls work together, quality protects patients); typical GMP documentation (batch manufacturing record, SOPs, specifications and test methods, equipment and calibration logs, cleaning records, change control and CAPA records, training records, quality agreements, certificates of analysis); and discussion questions." class="" loading="lazy" decoding="async" /> </picture> <h2 id="the-one-idea">The one idea</h2> <p>The sections before this one are about the <em>result</em>: is the shelf life real (<a href="https://temple-quality-in-pharma.scribe-it.app/2026-lecture/1-sep14/3-regulations/q1-stability/">Q1</a>), can the measurement be trusted (<a href="https://temple-quality-in-pharma.scribe-it.app/2026-lecture/1-sep14/3-regulations/q2-validation/">Q2</a>), is the impurity safe (<a href="https://temple-quality-in-pharma.scribe-it.app/2026-lecture/1-sep14/3-regulations/q3-impurities/">Q3</a>), is the limit on the list defensible (<a href="https://temple-quality-in-pharma.scribe-it.app/2026-lecture/1-sep14/3-regulations/q6-specifications/">Q6</a>). <strong>Q7 is about the system that produced the result.</strong> A correct number from an uncalibrated instrument, an untrained analyst, an unvalidated method, or a batch record written from memory a week later is not evidence of anything.</p>https://temple-quality-in-pharma.scribe-it.app/2026-lecture/1-sep14/3-regulations/q8-q12-development-lifecycle/Mon, 07 Sep 2026 00:00:00 +0000https://temple-quality-in-pharma.scribe-it.app/2026-lecture/1-sep14/3-regulations/q8-q12-development-lifecycle/<picture><source type="image/avif" srcset="https://temple-quality-in-pharma.scribe-it.app/2026-lecture/1-sep14/3-regulations/q8-q12-development-lifecycle/image_hu_b31f69253f2bf286.avif 400w, https://temple-quality-in-pharma.scribe-it.app/2026-lecture/1-sep14/3-regulations/q8-q12-development-lifecycle/image_hu_3923447efa728122.avif 800w, https://temple-quality-in-pharma.scribe-it.app/2026-lecture/1-sep14/3-regulations/q8-q12-development-lifecycle/image_hu_26e8197e9239dd95.avif 1200w, https://temple-quality-in-pharma.scribe-it.app/2026-lecture/1-sep14/3-regulations/q8-q12-development-lifecycle/image_hu_7a624346b052184d.avif 1600w" sizes="100vw"><source type="image/webp" srcset="https://temple-quality-in-pharma.scribe-it.app/2026-lecture/1-sep14/3-regulations/q8-q12-development-lifecycle/image_hu_5a8b3aefe047a4b2.webp 400w, https://temple-quality-in-pharma.scribe-it.app/2026-lecture/1-sep14/3-regulations/q8-q12-development-lifecycle/image_hu_7eb455a9ba6d8e78.webp 800w, https://temple-quality-in-pharma.scribe-it.app/2026-lecture/1-sep14/3-regulations/q8-q12-development-lifecycle/image_hu_1058f4ea46d4fdc8.webp 1200w, https://temple-quality-in-pharma.scribe-it.app/2026-lecture/1-sep14/3-regulations/q8-q12-development-lifecycle/image_hu_4e700b8edcc22115.webp 1600w" sizes="100vw"><img src="https://temple-quality-in-pharma.scribe-it.app/2026-lecture/1-sep14/3-regulations/q8-q12-development-lifecycle/image_hu_a21c4ed6daef7e37.png" srcset="https://temple-quality-in-pharma.scribe-it.app/2026-lecture/1-sep14/3-regulations/q8-q12-development-lifecycle/image_hu_bb1ef12c5b62ec24.png 400w, https://temple-quality-in-pharma.scribe-it.app/2026-lecture/1-sep14/3-regulations/q8-q12-development-lifecycle/image_hu_a21c4ed6daef7e37.png 800w, https://temple-quality-in-pharma.scribe-it.app/2026-lecture/1-sep14/3-regulations/q8-q12-development-lifecycle/image_hu_227e096d7922dc7e.png 1200w, https://temple-quality-in-pharma.scribe-it.app/2026-lecture/1-sep14/3-regulations/q8-q12-development-lifecycle/image_hu_9344c4aa4947050b.png 1600w" sizes="100vw" alt="One-page overview of ICH Q8–Q12 — Development, Risk, Quality System &amp; Lifecycle, subtitled &#39;Design Understanding. Manage Risk. Enable a Better Future.&#39; and &#39;a harmonised pharmaceutical quality framework across the product lifecycle, emphasising an integrated approach to quality risk management and science.&#39; Panels: the one idea (Q1–Q7 judge the result after the fact; Q8–Q12 are about designing the process so the result is right by construction and managing it for the life of the product) with a quality-by-testing versus quality-by-design table — where quality comes from (test at the end vs. built in by design), the specification (primary assurance vs. one element of a control strategy), process changes (re-file and wait vs. move within the design space or use pre-agreed changes), and the regulator&#39;s view (check the result vs. check process understanding); the Q8–Q12 family at a glance (Q8(R2) Pharmaceutical Development, Step 4 Aug 2009 — define the target, identify CQAs, understand inputs, establish a design space and control strategy; Q9(R1) Quality Risk Management, Step 4 Jan 2023 — a structured science-based process to identify, assess, control and review risks, with tools FMEA, FMECA, FTA, HAZOP; Q10 Pharmaceutical Quality System, Step 4 June 2008 — management responsibility and the four elements monitoring, CAPA, change management, management review; Q11 Development and Manufacture of Drug Substances, Step 4 May 2012 — small-molecule and biotech APIs, starting-material selection and justification; Q12 Lifecycle Management, Step 4 Nov 2019 — established conditions, the PLCM document, post-approval change management); how they fit together (Q8 QTPP → CQAs → design space → control strategy; Q9 identify → assess → control → review; Q10 monitoring, CAPA, change management, management review; Q11 starting materials, route, process design and control; Q12 established conditions, post-approval changes, continual improvement — all supported by science, documented in the CTD, enabling flexible risk-based regulation); the product lifecycle wheel — develop, control, launch, manage, improve (continuous) — around &#39;safe, effective medicines for patients&#39;; Q8 Pharmaceutical Development (key concepts QTPP, CQAs, CMAs, CPPs, DOE, design space, control strategy, lifecycle and continual improvement; an example design-space response surface of a quality attribute versus temperature and pH, with the instruction to operate within the design space to consistently meet CQAs); Q9 Quality Risk Management (the four-step process identify, assess, control, review; tools FMEA/FMECA, fault tree analysis, HAZOP, Ishikawa/fishbone, risk ranking and criticality, what-if analysis, control diagrams, prior knowledge; formal, transparent and science-based per Q9(R1)); Q10 Pharmaceutical Quality System (four key elements — monitoring of process performance and product quality, corrective and preventive action, change management, management review — with management responsibility and a culture of quality enabling regulatory flexibility); Q11 Drug Substance Development (starting-material selection and justification, route selection and synthetic scheme, control of process-related impurities, process development and scale-up and technology transfer, control strategy for the drug substance, biotech considerations linked to the quality system); Q12 Lifecycle Management (established conditions — what can change without approval; the Product Lifecycle Management document; post-approval change categories; continual improvement using new knowledge and data); Section 3.2.P — the CTD development story as a flow: QTPP and product overview → risk management (Q9) → design space and control strategy (Q8) → drug-substance information (Q11) → lifecycle and commitments (Q12), a clear logical science-based story that builds regulator confidence; the business case for QbD (stronger assurance, greater efficiency, more innovation, fewer post-approval changes, more productive inspections); five discussion questions; and a footer band reading Science &#43; Risk Management &#43; Quality System &#43; Lifecycle = Better Medicines for Patients." class="" loading="lazy" decoding="async" /> </picture> <h2 id="the-one-idea">The one idea</h2> <p>Everything before this section judges a result after the fact: is the shelf life real (<a href="https://temple-quality-in-pharma.scribe-it.app/2026-lecture/1-sep14/3-regulations/q1-stability/">Q1</a>), can the measurement be trusted (<a href="https://temple-quality-in-pharma.scribe-it.app/2026-lecture/1-sep14/3-regulations/q2-validation/">Q2</a>), is the impurity safe (<a href="https://temple-quality-in-pharma.scribe-it.app/2026-lecture/1-sep14/3-regulations/q3-impurities/">Q3</a>), is the limit defensible (<a href="https://temple-quality-in-pharma.scribe-it.app/2026-lecture/1-sep14/3-regulations/q6-specifications/">Q6</a>), is the system that produced it under control (<a href="https://temple-quality-in-pharma.scribe-it.app/2026-lecture/1-sep14/3-regulations/q7-gmp-api/">Q7</a>). <strong>Q8–Q12 are about designing the process so the result is right by construction, and then managing that process for the life of the product.</strong></p>https://temple-quality-in-pharma.scribe-it.app/2026-lecture/1-sep14/3-regulations/q13-continuous-manufacturing/Sun, 06 Sep 2026 00:00:00 +0000https://temple-quality-in-pharma.scribe-it.app/2026-lecture/1-sep14/3-regulations/q13-continuous-manufacturing/<picture><source type="image/avif" srcset="https://temple-quality-in-pharma.scribe-it.app/2026-lecture/1-sep14/3-regulations/q13-continuous-manufacturing/image_hu_50221779293f95ed.avif 400w, https://temple-quality-in-pharma.scribe-it.app/2026-lecture/1-sep14/3-regulations/q13-continuous-manufacturing/image_hu_95f4b2d1ea2ea46d.avif 800w, https://temple-quality-in-pharma.scribe-it.app/2026-lecture/1-sep14/3-regulations/q13-continuous-manufacturing/image_hu_312efe4501718fcc.avif 1200w, https://temple-quality-in-pharma.scribe-it.app/2026-lecture/1-sep14/3-regulations/q13-continuous-manufacturing/image_hu_bbb8b52c0cfa5571.avif 1600w" sizes="100vw"><source type="image/webp" srcset="https://temple-quality-in-pharma.scribe-it.app/2026-lecture/1-sep14/3-regulations/q13-continuous-manufacturing/image_hu_31b27d0f7bf24f26.webp 400w, https://temple-quality-in-pharma.scribe-it.app/2026-lecture/1-sep14/3-regulations/q13-continuous-manufacturing/image_hu_a9ecfd5c123f8e0b.webp 800w, https://temple-quality-in-pharma.scribe-it.app/2026-lecture/1-sep14/3-regulations/q13-continuous-manufacturing/image_hu_f95744fd6688956.webp 1200w, https://temple-quality-in-pharma.scribe-it.app/2026-lecture/1-sep14/3-regulations/q13-continuous-manufacturing/image_hu_7bbd7abfcd925af8.webp 1600w" sizes="100vw"><img src="https://temple-quality-in-pharma.scribe-it.app/2026-lecture/1-sep14/3-regulations/q13-continuous-manufacturing/image_hu_3a0f84297d28cf6f.png" srcset="https://temple-quality-in-pharma.scribe-it.app/2026-lecture/1-sep14/3-regulations/q13-continuous-manufacturing/image_hu_f81926448a52e8e0.png 400w, https://temple-quality-in-pharma.scribe-it.app/2026-lecture/1-sep14/3-regulations/q13-continuous-manufacturing/image_hu_3a0f84297d28cf6f.png 800w, https://temple-quality-in-pharma.scribe-it.app/2026-lecture/1-sep14/3-regulations/q13-continuous-manufacturing/image_hu_59e1d6a48636aa27.png 1200w, https://temple-quality-in-pharma.scribe-it.app/2026-lecture/1-sep14/3-regulations/q13-continuous-manufacturing/image_hu_63a6afd5b0e2d360.png 1600w" sizes="100vw" alt="One-page overview of ICH Q13 continuous manufacturing. Panels cover: the one idea (a continuous process feeds material in and takes product out at the same time, so the release decision moves onto the line in real time; Q13 does not require CM, it removes the excuse that regulators can&#39;t review it); batch vs. continuous, same unit operations run a different way, with a diagram of four discrete batch steps versus a linked continuous train; the Q13 guideline (title, Step 4 on 16 November 2022 adopted by FDA and EMA in 2023, scope of chemical entities and therapeutic proteins, out of scope other biologics and upstream perfusion culture, read alongside Q8-Q12, Q2(R2), Q14, Q7 and Q6; illustrative annex examples); why continuous (consistent quality, higher efficiency, lower cost of goods, faster and more resilient supply, improved patient access, smaller environmental footprint, plus regulatory flexibility); what changes in CM as a batch-versus-continuous table for unit of quality, residence time, disturbances, traceability, state of control, scale-up and startup/shutdown; residence time distribution shown as a sharp input pulse becoming a broad lower output curve, used to calculate how long a disturbance takes to reach the outlet and how much material to divert; the CM control strategy (design, real-time monitoring, material traceability, batch definition, divert non-conforming material, real-time release testing, lifecycle management); batch definition (a defined quantity produced under controlled conditions, definable by time, mass or a combination); data integrity and ALCOA&#43;; approved products that pioneered CM (Janssen Prezista 2015, Vertex Orkambi 2015, and later FDA and EMA approvals); end-to-end integration of drug substance and drug product; reprocessing versus reworking; and discussion questions. Note: some words in the generated graphic are garbled." class="" loading="lazy" decoding="async" /> </picture> <h2 id="the-one-idea">The one idea</h2> <p>A batch process makes a <strong>discrete quantity</strong> of material in a sequence of contained steps, and quality is judged step by step and at the end. A continuous process feeds material in and takes product out <strong>at the same time, continuously, for hours or days</strong>, with the unit operations physically linked. There is no lot sitting in a drum waiting for a release decision — so the release decision has to move <strong>onto the line, in real time</strong>.</p>https://temple-quality-in-pharma.scribe-it.app/2026-lecture/1-sep14/3-regulations/q14-analytical-procedure-development/Sun, 06 Sep 2026 00:00:00 +0000https://temple-quality-in-pharma.scribe-it.app/2026-lecture/1-sep14/3-regulations/q14-analytical-procedure-development/<div class="pageinfo pageinfo-primary"> <p>Full write-up. A one-page overview graphic on par with the <a href="https://temple-quality-in-pharma.scribe-it.app/2026-lecture/1-sep14/3-regulations/q1-stability/">Q1</a> and <a href="https://temple-quality-in-pharma.scribe-it.app/2026-lecture/1-sep14/3-regulations/q2-validation/">Q2</a> pages is still to be produced.</p> </div> <h2 id="the-one-idea">The one idea</h2> <p>An analytical procedure is a <strong>design problem</strong>, not a recipe you inherit. Before you choose a technique, you write down what the measurement has to achieve — what it measures, in what, over what range, and how well — and then you develop a procedure <em>against that requirement</em> and prove it meets it.</p>